Anal Cancer Survival Rates and Prognosis: What the Numbers Mean

If you or someone you love has just been diagnosed, survival numbers are probably the first thing you searched for. That is a normal reaction. It helps to know up front that the overall outlook for anal cancer is better than many people expect, and that most people who are diagnosed are cured.

How Common Is Anal Cancer?

Anal cancer is uncommon. The American Cancer Society estimates that in 2026 there will be about 11,270 new cases of anal cancer in the United States, and about 1,700 deaths. Broken down by sex, that is about 7,700 new cases in women and 3,570 in men, and about 1,130 deaths in women and 570 in men. Anal cancer makes up about 0.5% of all new cancer cases in the United States, according to the National Cancer Institute's SEER program (SEER stands for Surveillance, Epidemiology, and End Results, the national cancer registry that tracks cancer cases and outcomes).

Those numbers show something many people do not realize. Anal cancer is more common in women than in men in the United States. It is often wrongly assumed to be a cancer only of gay men, or only of people with HIV. That is not true. Anyone with an anus can develop anal cancer. Most people diagnosed with it are older adults, and the majority are women.

Anal cancer is rare in people younger than 35. The American Cancer Society describes it as found mainly in older adults, with an average age in the early 60s. SEER data show it is most often diagnosed in people aged 55 to 64. About 31% of new cases are found in that age group and another 28% in people aged 65 to 74. Fewer than 6% of cases occur in people under 45.

The trend over time needs care, because different sources describe it differently and both are correct. The American Cancer Society states that the number of new anal cancer cases has been rising for many years, and StatPearls reports incidence rising at roughly 2.7% a year over the past decade. At the same time, SEER's own analysis found that age-adjusted rates for new anal cancer cases did not change significantly from 2012 to 2021. Age-adjusted means the rate has been mathematically corrected for the fact that populations get older over time. So the honest summary is this: the raw number of people diagnosed each year has grown a great deal over recent decades, partly because the population is larger and older, while the most recent decade of age-adjusted rates has been roughly flat. SEER also found that age-adjusted death rates have been rising an average of 5.1% each year from 2013 to 2022, which is a real concern and one reason anal cancer screening matters for higher-risk groups.

Risk is not spread evenly. The National Cancer Institute reports that during 2015 to 2019, people living with HIV in the United States were nearly 20 times as likely to be diagnosed with anal cancer as people in the general population. That is why the Department of Health and Human Services recommends anal cancer screening for people living with HIV starting at age 35 for men who have sex with men and certain other higher-risk groups, and starting at age 45 for everyone else with HIV. The ANCHOR trial, sponsored by the National Cancer Institute, found that treating anal high-grade squamous intraepithelial lesions (abnormal precancer cells in the anal lining, often shortened to HSIL) lowers the risk of those lesions turning into cancer in people living with HIV. You can read more in our guide to risk factors for anal cancer.

Anal cancer is uncommon outside the United States too, and the same patterns show up. Cancer Research UK reports around 1,700 new anal cancer cases in the United Kingdom each year, about 5 a day, and around 530 deaths. In the UK, incidence rates have increased by about 91% since the early 1990s, with rates in women more than doubling, up 136%, and rates in men up 38%. Cancer Research UK also reports that 91% of UK anal cancer cases are considered preventable and that HPV is linked to about 90 out of 100 UK cases. In the United States, the CDC estimates that about 91% of anal cancers are caused by HPV, higher than for most other HPV-related cancers. HPV is an extremely common virus. Nearly everyone who has been sexually active has been exposed to it, so carrying it is not a moral failing or a sign of anything you did wrong.

What Is the Survival Rate for Anal Cancer?

Before the numbers, please understand what they are. A five-year relative survival rate compares people who have a certain type and stage of cancer to people in the general population of the same age. The American Cancer Society explains it this way: if the five-year relative survival rate for a stage of anal cancer is 80%, it means people with that cancer are, on average, about 80% as likely as people without it to live at least five years after diagnosis. It is not a countdown clock, and it is not a prediction that you will live exactly five years. Many people live far longer than five years, and five years is simply the standard window researchers use so that studies can be compared.

These figures have real limits, and you deserve to know them before you look.

1. They come from people who were diagnosed years ago, so they reflect treatments that were standard then, not the newest ones.

2. They group together people with very different situations, ages, other health conditions, and treatments.

3. Relative survival is designed to filter out deaths from unrelated causes, but no statistical method is perfect, and the underlying groups still include people who died of things that had nothing to do with their cancer.

4. Most important, these are averages across large groups of people. As SEER puts it, because survival statistics are based on large groups, they cannot be used to predict exactly what will happen to an individual patient. No two people are alike, and responses to treatment vary greatly.

SEER does not group cases by stage 1, stage 2, and stage 3. Instead, it uses three broader groups. Localized means there is no sign the cancer has spread outside the anal area. Regional means it has spread to nearby structures or lymph nodes (small glands that help fight infection). Distant means it has spread to faraway parts of the body such as the liver or lungs. Here are the American Cancer Society's and SEER's published relative survival rates for anal cancer

SEER also reports that 66.8% of cases with an unknown stage survive five years or more. The closeness of these two sets of numbers is reassuring, because it means the estimate is stable and not an artifact of one particular dataset.

Here is a fact that gets lost in the fear. Most people with anal cancer are not diagnosed at the distant stage. According to SEER, about 41% of cases are found while still localized and about 36% are found at the regional stage. That means roughly 77% of people are diagnosed at a localized or regional stage, where five-year relative survival is between about 68% and 85%. Only about 14% are diagnosed after the cancer has spread to distant parts of the body. Learning where you fall in our guide to anal cancer stages will tell you far more than any average that combines all stages.

Within a stage, two things predict outcome more strongly than anything else. The National Cancer Institute states plainly that the two major prognostic factors for anal cancer are tumor size and nodal status, meaning whether cancer is found in nearby lymph nodes. Tumors smaller than 2 cm have a better prognosis. NCI also notes that at the time of diagnosis, most patients have T1 or T2 disease, meaning a tumor 5 cm or smaller, and fewer than 20% have cancer in their lymph nodes. For those patients with early disease, the five-year survival rate is above 85%. Even when lymph nodes are involved, five-year survival rates are above 50% as long as the cancer has not invaded nearby organs or spread to distant sites. Other things matter too, including your overall health, whether you are able to complete treatment on schedule, and whether you have HIV that is well controlled. Your own care team, looking at your imaging, your biopsy, and your health history, can tell you far more about your situation than any published table can.

Is Anal Cancer Curable?

Yes. The National Cancer Institute states directly that anal cancer is usually curable. That sentence is worth reading twice, because it is not how most people expect a cancer page to read. For most stage I, stage II, and stage III anal cancer, the goal of treatment is cure, and it is reached most of the time.

What may surprise you is how it is cured. For most anal cancers, the standard treatment is not surgery. It is chemoradiation, which means radiation therapy given together with chemotherapy. The National Cancer Institute describes chemoradiation as the standard of care for stage I, II, and III anal cancer in appropriate patients, and as the preferred approach when the cancer has not spread to distant sites. The reason this matters so much to daily life is that chemoradiation usually preserves the anus. In the trial data NCI cites, at five years 75% of people treated with chemoradiation were still living without a colostomy, compared with 48% of people treated the older way, which led with surgery. A colostomy is an opening made in the belly wall so stool can leave the body into a pouch. Most people treated for anal cancer today never need one. This is a genuine difference between anal cancer and colorectal cancer, which are separate diseases with different treatments. Our guide to anal cancer treatment explains what to expect step by step.

Three words get used loosely, and knowing the difference will help you understand what your team tells you. No evidence of disease means that after treatment, exams, scans, and biopsies find no sign of cancer. Doctors often say NED. Remission means the cancer has shrunk or disappeared, and it can be partial or complete. Cure means the cancer is gone and will not come back. The hard part is that cure can only be known with time, so your team may say NED for months or years before anyone uses the word cure. With anal cancer, there is an extra wrinkle worth knowing about. Tumors sometimes shrink slowly after chemoradiation, so your doctor may wait up to about six months before deciding whether treatment fully worked, rather than calling it a failure too early. That waiting period is normal and is not bad news.

If cancer does persist after chemoradiation or comes back later, cure is still on the table. This is important, because many people assume a recurrence means the end of hope. It does not. The National Cancer Institute describes abdominoperineal resection, a surgery that removes the anus and rectum and creates a permanent colostomy, as the standard salvage therapy for people who have cancer remaining after chemoradiation. Salvage means treatment given to cure the disease after a first treatment did not fully succeed. NCI also lists other options depending on the situation, including additional chemoradiation, chemotherapy alone, or immunotherapy, and notes that salvage chemoradiation with a radiation boost may let some people avoid a permanent colostomy. Surgery in anal cancer is a backup plan, not the default first step.

Metastatic anal cancer, meaning cancer that has spread to distant organs, is generally not considered curable. It is, however, very treatable, and treatment can extend life meaningfully while controlling symptoms. The National Cancer Institute notes there is no single clear standard of care for metastatic disease but that recent studies are uncovering promising new avenues for systemic treatment. Systemic means treatment that travels through the whole body. In the international InterAACT trial, carboplatin with weekly paclitaxel produced a median overall survival of 20 months compared with 12.3 months for the older combination of fluorouracil and cisplatin. Immunotherapy, which helps your own immune system recognize and attack cancer, has also shown activity here, and NCI lists the checkpoint inhibitors nivolumab and pembrolizumab among the options for metastatic disease. If you are in this situation, ask your team about joining a clinical trial for anal cancer, because this is an area where research is moving quickly.

Of everything on this page, one factor is more within your control than any other, and it is timing. Early anal cancer causes bleeding, itching, pain, a lump, or a change in bowel habits, and these are exactly the symptoms of hemorrhoids. Many people wait months, treating themselves with drugstore creams, because they assume that is all it is or because they feel too embarrassed to bring it up. That delay is the single most changeable thing in this whole picture, and it moves people from the 85% column to the 36% column. If you have bleeding, pain, a lump, or a change in bowel habits that has lasted more than a few weeks, ask for an exam, and ask again if you are brushed off. Learn what to watch for in our guide to anal cancer symptoms and what happens next in how is anal cancer diagnosed. Nothing here is medical advice for your situation. Please use it as a starting point for a conversation with your own care team, who know your case, and lean on the people and groups in our guide to anal cancer support while you do.

Sources:

• Cancer Stat Facts: Anal Cancer, National Cancer Institute SEER Program

• Key Statistics for Anal Cancer, American Cancer Society

• Anal Cancer Survival Rates, American Cancer Society

• Anal Carcinoma, StatPearls, NCBI Bookshelf

• Anal Cancer Statistics, Cancer Research UK

• Anal Cancer Incidence Statistics, Cancer Research UK